Anorexia iN Cancer Patients: ANCHOR

Gastric Cancer Clinical Trial

— ANCHOR  

Official title:

Anorexia iN Cancer Patients: Assessment of the Gut HORmone and Cytokine Profile and Body Composition, and the Impact of Dietetic Support in Patients With Gastrointestinal Cancer. (ANCHOR Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04791254
• Other study ID #: CFTSp141
• Status: Recruiting
• Start date: July 15, 2021
• Est. completion date: April 2026

Study information

• Verified date: February 2023
• Source: The Christie NHS Foundation Trust
• Contact: Alexandra Lewis
• Phone: +44 161 918 7887
• Email: alexandra.lewis12[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The rationale for this study is to prospectively investigate the outcomes of patients undergoing standard dietetic interventions alongside treatment for their advanced gastrointestinal cancers, and to further characterise the relationship with body composition.

A number of patients will be enrolled in a sub-study investigating the neuronal-enteroendocrine-hypothalamic axis.

Gut hormone study. Our hypothesis is that proinflammatory cytokines produced by the tumour can not only affect appetite directly through the vagal and the central melanocortin system but also indirectly though the enhanced EEC activity; either through increased number or increased function.

In this study, the investigators will explore and compare the pattern and levels (pre-prandial and post prandial) of the pro-inflammatory cytokines and gut hormones between stage-standardised anorexic and non-anorexic cancer patients and age-matched healthy controls.

Description:

Poor nutritional status contributes significantly to poor outcomes in patients with upper GI cancers, in some patients, directly leading to death. Poor fitness, in terms of reduced muscle mass (sarcopenia) or physical performance, is associated with higher treatment toxicity and poor treatment outcomes.

However the relationship between different markers of nutritional status and body composition with fitness is not fully understood. It is also not known what impact dietetic interventions have on the reduced survival seen in patients with weight loss at baseline.

Finally, the underlying interaction between the neuronal-enteroendocrine-hypothalamic axis that regulates appetite is poorly understood but believed to be impaired in patients with upper GI cancers because of a number of altered mechanisms.

Therefore the rationale for this study is to prospectively investigate the outcomes of patients undergoing standard dietetic interventions alongside treatment for their advanced gastrointestinal cancers, and to further characterise the relationship with body composition.

A number of patients will be enrolled in a sub-study investigating the neuronal-enteroendocrine-hypothalamic axis.

The hypothesis is that proinflammatory cytokines produced by the tumour can not only affect appetite directly through the vagal and the central melanocortin system but also indirectly though the enhanced EEC activity; either through increased number or increased function.

In this study, the investigators will explore and compare the pattern and levels (pre-prandial and post prandial) of the pro-inflammatory cytokines and gut hormones between stage-standardised anorexic and non-anorexic cancer patients and age-matched healthy controls.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: April 2026
• Est. primary completion date: April 2025
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inclusion criteria: Cohort A

1. Patients with stage IV gastric or GOJ adenocarcinoma or locally advanced non-resectable adenocarcinoma

2. Histologically proven adenocarcinoma, squamous cell carcinoma or poorly differentiated carcinoma

3. Patients should be chemotherapy or immune therapy naïve (for their current diagnosis).

4. Patient must be 18 years of age or above.

5. Patient must be able to understand the study information given to them and be willing to give consent for trial participation.

6. Patients should be commencing a course of palliative chemotherapy treatment with the upper GI team at the Christie Hospital

In addition the above patients enrolled in cohort B must meet the following criteria

Inclusion criteria: Cohort B

1. Be physically able to perform moderate exercise (to their own tolerance) on a stationary bicycle or treadmill

In addition to the above patients in cohort C must meet the following criteria

Inclusion Criteria: Cohort C

1. Histologically proven adenocarcinoma or poorly differentiated carcinoma

2. Patients should be chemotherapy or immune therapy naïve.

3. Patients must be able and willing to fast for 8-10 hours. 4 5.1 Patients in the anorexic group must have completed the FAACT AC/S questionnaire and scored =24 in total score and = 2 in the appetite specific question.

5.2 For inclusion in the non-anorexic group patients must have completed the FAACT AC/S questionnaire; the total score should be > 37 and =3 for the appetite specific question.

Inclusion criteria: Cohort D - healthy controls

1. Participants must be 18 years of age or above.

2. Participants must be able and willing to fast for 8-10 hours.

3. Participants must be able to understand the study information given to them and be willing to give consent for trial participation.

4. Participants must have completed the FAACT AC/S questionnaire and scored =24 in total score and = 2 in the appetite specific question, for the anorexic group. For inclusion in the non-anorexic group the total score should be > 37 and =3 for the appetite specific question.

Exclusion Criteria:

• Participants are excluded from the study if any of the following criteria apply:

Exclusion criteria Cohort A:

1. Patients unable to give informed consent

2. Patients not undergoing systemic anti-cancer treatment at The Christie hospital, for example patients not deemed fit enough for treatment, patients having alternative treatments such as radiotherapy or surgery, or patients referred for 2nd opinions.

Exclusion criteria Cohort B:

1. Recent myocardial infarction or stroke

2. Recent abdominal, eye or thoracic surgery

3. A recent respiratory tract infection (within 3 weeks)

4. Any chest pain on the day of the test

5. A positive COVID-19 test

Exclusion Criteria Cohort C & D : all patients and healthy volunteers

1. Symptoms of dysphagia of any cause, oesophageal or gastric obstruction (assessed via medical history/O'Rourke score). Patients with O'Rourke score =2 will be excluded.

2. Presence of oesophageal stent or any other kind of feeding aid (nasogastric tube, nasoduodenal tube, gastrostomy, jejunostomy)

3. Presence of brain metastases or any kind of brain tumor including benign pituitary adenomas.

4. Histological diagnosis of neuroendocrine tumor, or mixed tumor.

5. Previous gastro-duodenal surgery.

6. History of Inflammatory Bowel Disease (Ulcerative colitis, Crohn's disease).

7. History of Coeliac disease.

8. History of endocrine disease (Diabetes mellitus, Thyroid disease, Cushing's)

9. Significant past or present eating disorder e.g. anorexia nervosa, bulimia nervosa.

10. Current active infection (general or intestinal).

11. Chronic use of immunomodulatory drugs (steroids, immunosuppressant drugs, recent use of corticosteroids would require a two week washout period prior to study assessments).

12. Chronic use of NSAIDS or aspirin. (Periodic use can be accepted).

13. Patients with pacemakers. (Contraindication for BIA).

14. Allergy to any of the ingredients of the meal test or unwillingness to consume the particular meal (Heinz Chicken soup or Heinz Mushroom soup).

Related Conditions & MeSH terms

• Anorexia
• Gastric Cancer
• Oesophageal Cancer

Locations

Country	Name	City	State
United Kingdom	The Christie NHS Foundation Trust	Manchester

Sponsors (3)

Lead Sponsor	Collaborator
The Christie NHS Foundation Trust	Manchester Metropolitan University, University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival outcomes in patients with advanced upper gastrointestinal cancers receiving dietetic interventions.	Progression free and overall survival from diagnosis.	Through study completion, median expected overall survival < 1 year.
Primary	Differences in patterns of plasma gut hormone and cytokine levels as measured by ELISA between study participants.	Plasma gut hormones and cytokine levels as measured via ELISA including, ghrelin, insulin, GLP-1, PYY, pancreatic polypeptide, GIP, CHromogranin A, CCK. The following cytokines will be included. IL-1, IL-6, TNF-a	3 months from completion of data collection
Secondary	Correlation between hormonal and cytokine profile and body composition as measured by bioelectrical impedance analysis and CT measured muscle mass (for patients only) and density.		Within 6 months of completion of data collection
Secondary	Correlation between nutritional status, body composition and physical fitness		Within 6 months of completion of data collection